Organization (Other)
The Emmes Company, LLC
ClinicalTrials.gov lists The Emmes Company, LLC as lead sponsor of 11 trials. It has 12 active development programs and 7 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 5 registered with a 2026 start date. The dashed outline is the pace from the 5 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.0 trial starts a year over the five years to September, under the 5 a year the method needs. 2 trials are registered to start in 2027 or later.
This page covers The Emmes Company, LLC: 11 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (168)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| HIV Infections | 27 |
| Substance-Related Disorders | 25 |
| Opioid-Related Disorders | 22 |
| Lymphoma | 13 |
| Lymphoma, Non-Hodgkin | 9 |
Showing 5 of 168 disease areas.
Trials by start year as sponsor or collaborator (23)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2024 | 6 |
| 2023 | 4 |
| 2022 | 3 |
| 2021 | 13 |
| 2020 | 8 |
| 2019 | 7 |
| 2018 | 9 |
| 2017 | 7 |
| 2016 | 3 |
Showing 10 of 23 years.
Recruitment duration, a model prediction: none of the 11 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (12)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Lorazepam | Critical Illness | Phase 2/3 | 1 |
| MIDAZOLAM | Critical Illness | Phase 2/3 | 1 |
| Lorazepam CI | Critical Illness | Phase 2/3 | 1 |
| Nitroprusside | Hypotension | Phase 2 | 1 |
| Sham Therapy | Venous Thrombosis | Phase 1/2 | 1 |
Showing 5 of 12 active programs.
Approved assets (7)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| BEVACIZUMAB | 1 |
| AFLIBERCEPT | 1 |
| Lorazepam | 1 |
| MIDAZOLAM | 1 |
| Nitroprusside | 1 |
Showing 5 of 7 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 60% hit target (n=5) | 20% on time (n=5) |
Journals published in (272)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Stroke | 18 |
| The New England journal of medicine | 17 |
| PloS one | 13 |
| American journal of ophthalmology | 11 |
| Diseases of the colon and rectum | 11 |
Showing 5 of 272 journals.
Financing and grant events (77)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-30 | NIH grant | 561,958 | Reporter |
| 2025-09-30 | NIH grant | 9,200,000 | Reporter |
| 2025-09-30 | NIH grant | 8,960,000 | Reporter |
| 2025-09-30 | NIH grant | 26,737,744 | Reporter |
| 2025-09-30 | NIH grant | 267,558 | Reporter |
Showing 5 of 77 events.
Organization relationships (12)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Weill Medical College of Cornell University | Co sponsors trial with | 2 |
| University of California | Co sponsors trial with | 1 |
| Coalition to Cure Calpain 3 (C3) | Co sponsors trial with | 1 |
| Calibr, a division of Scripps Research | Co sponsors trial with | 1 |
| Henry M. Jackson Foundation for the Advancement of Military Medicine | Co sponsors trial with | 1 |
Showing 5 of 12 relationships.
Latest dated events (228)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-04-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 228 events.
Biomarker capability evidence (632)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCD2 | Trial collaborator | Named in trial inclusion criteria |
| ABCD2 | Trial CRO (operations) | Named in trial inclusion criteria |
| ACE | Trial collaborator | Named in trial inclusion criteria |
| ACE | Trial CRO (operations) | Named in trial inclusion criteria |
| BCAR1 | Trial CRO (operations) | Named in trial inclusion criteria |
Showing 5 of 632 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.